Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
The loss of PTEN and phosphorylated Akt (pAkt) expression is thought to be involved in the mechanism leading to trastuzumab resistance in patients with HER2-positive breast cancer. We retrospectively performed immunohistochemical analyses for estrogen receptor, progesterone receptor, HER2/neu, PTEN, pAkt, and p53 expression in tumor specimens obtained before and after trastuzumab-containing neo-adjuvant chemotherapy. The intensity of staining was evaluated for each biomarker, and the correlations between the immunohistochemical profiles and the clinical outcome were analyzed. The changes in the immunohistochemical profiles between specimens obtained before and after trastuzumab-containing neo-adjuvant chemotherapy were evaluated for patients with residual tumors. The present study included 44 patients with breast cancer who received trastuzumab-containing neo-adjuvant chemotherapy. Seventeen patients achieved a pathological complete response. The patients were positive for PTEN and pAkt (PTEN = 14%, N = 6/44; pAkt, 80%, N = 35/44). The expression of both PTEN and pAkt were not correlated with pathological complete response. Persistent HER2/neu over-expression after neo-adjuvant chemotherapy was significantly associated with recurrence. Among 27 patients with residual cancer, the percentages of patients with HER2/neu-positive or pAkt-positive tumors were low, but PTEN expression was elevated. The present study suggested that neither the immunohistochemical expression of PTEN nor the expression of pAkt was associated with the clinical outcome of trastuzumab-containing neo-adjuvant chemotherapy. Except among patients with pathological complete remission, the persistent over-expression of HER2/neu may be a poor prognostic factor.
Yonemori
Kan
K
Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. kyonemor@ncc.go.jp
Tsuta
Koji
K
Shimizu
Chikako
C
Hatanaka
Yutaka
Y
Hashizume
Kaoru
K
Ono
Makiko
M
Kouno
Tsutomu
T
Ando
Masashi
M
Tamura
Kenji
K
Katsumata
Noriyuki
N
Hasegawa
Tadashi
T
Kinoshita
Takayuki
T
Fujiwara
Yasuhiro
Y
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis*; D017239:Paclitaxel / Q000008:administration & dosage; D010766:Phosphorylation; D016133:Polymerase Chain Reaction; D051057:Proto-Oncogene Proteins c-akt / Q000096:biosynthesis*; D012189:Retrospective Studies; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D000068878:Trastuzumab; D017239:Paclitaxel